John Marsden

John Marsden

Auto-generated profile, based on publicly available information

John Marsden

Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2008 in Addiction
Verified
Journal Article
Closed access
PDF file
RHRachel Humeniuk
Rachel Humeniuk
RARobert Ali
Robert Ali
TBThomas F. Babor
Thomas F. Babor
MFMichael Farrell
Michael Farrell
MFMaria L. Formigoni
Maria L. Formigoni
SSSara Simon
Sara Simon

10 May 2018 in Addiction
Verified
Journal Article
Open access
PDF file
APAmy Peacock
Amy Peacock
Janni LeungJanni Leung
Janni Leung
SLSarah Larney
Sarah Larney
SCSamantha Colledge
Samantha Colledge
MHMatthew Hickman
Matthew Hickman
LDLouisa Degenhardt
Louisa Degenhardt
Aims: This review provides an up‐to‐date curated source of information on alcohol, tobacco and illicit drug use and their associated mortality and burden of disease. Limitations in the data are also discussed, including how these can be addressed in the future.Methods: Online data sources were identified through expert review. Data were obtained mainly from the World Health Organization, United Nations Office on Drugs and Crime and Institute for Health Metrics and Evaluation.Results: In 2015, the estimated prevalence among the adult population was 18.4% for heavy episodic alcohol use (in the past 30 days); 15.2% for daily tobacco smoking; and 3.8, 0.77, 0.37 and 0.35% for past‐year cannabis, amphetamine, opioid and cocaine use, respectively. European regions had the highest prevalence of heavy episodic alcohol use and daily tobacco use. The age‐standardized prevalence of alcohol dependence was 843.2 per 100 000 people; for cannabis, opioids, amphetamines and cocaine dependence it was 259.3, 220.4, 86.0 and 52.5 per 100 000 people, respectively. High‐income North America region had among the highest rates of cannabis, opioid and cocaine dependence. Attributable disability‐adjusted life‐years (DALYs) were highest for tobacco smoking (170.9 million DALYs), followed by alcohol (85.0 million) and illicit drugs (27.8 million). Substance‐attributable mortality rates were highest for tobacco smoking (110.7 deaths per 100 000 people), followed by alcohol and illicit drugs (33.0 and 6.9 deaths per 100 000 people, respectively). Attributable age‐standardized mortality rates and DALYs for alcohol and illicit drugs were highest in eastern Europe; attributable age‐standardized tobacco mortality rates and DALYs were highest in Oceania.Conclusions: In 2015 alcohol use and tobacco smoking use between them cost the human population more than a quarter of a billion disability‐adjusted life years, with illicit drugs costing further tens of millions. Europeans suffered proportionately more, but in absolute terms the mortality rate was greatest in low‐ and middle‐income countries with large populations and where the quality of data was more limited. Better standardized and rigorous methods for data collection, collation and reporting are needed to assess more accurately the geographical and temporal trends in substance use and its disease burden.

5 August 2010 in Addiction
Verified
Journal Article
Open access
PDF file
EMElizabeth L. C. Merrall
Elizabeth L. C. Merrall
AKAzar Kariminia
Azar Kariminia
IBIngrid A. Binswanger
Ingrid A. Binswanger
MHMichael S. Hobbs
Michael S. Hobbs
MFMichael Farrell
Michael Farrell
SBSheila M. Bird
Sheila M. Bird
Aims  The transition from prison back into the community is particularly hazardous for drug‐using offenders whose tolerance for heroin has been reduced by imprisonment. Studies have indicated an increased risk of drug‐related death soon after release from prison, particularly in the first 2 weeks. For precise, up‐to‐date understanding of these risks, a meta‐analysis was conducted on the risk of drug‐related death in weeks 1 + 2 and 3 + 4 compared with later 2‐week periods in the first 12 weeks after release from prison.Methods  English‐language studies were identified that followed up adult prisoners for mortality from time of index release for at least 12 weeks. Six studies from six prison systems met the inclusion criteria and relevant data were extracted independently.Results  These studies contributed a total of 69 093 person‐years and 1033 deaths in the first 12 weeks after release, of which 612 were drug‐related. A three‐ to eightfold increased risk of drug‐related death was found when comparing weeks 1 + 2 with weeks 3–12, with notable heterogeneity between countries: United Kingdom, 7.5 (95% CI: 5.7–9.9); Australia, 4.0 (95% CI: 3.4–4.8); Washington State, USA, 8.4 (95% CI: 5.0–14.2) and New Mexico State, USA, 3.1 (95% CI: 1.3–7.1). Comparing weeks 3 + 4 with weeks 5–12, the pooled relative risk was: 1.7 (95% CI: 1.3–2.2).Conclusions  These findings confirm that there is an increased risk of drug‐related death during the first 2 weeks after release from prison and that the risk remains elevated up to at least the fourth week.

1 December 1998 in Addiction
Verified
Journal Article
Closed access
PDF file
JMJohn Marsden
John Marsden
MGMichael Gossop
Michael Gossop
DSDuncan Stewart
Duncan Stewart
DBDavid Best
David Best
MFMichael Farrell
Michael Farrell
JSJohn Strang
John Strang

1 August 2001 in Health Education Research
Verified
Journal Article
Open access
PDF file
ABAnnabel Boys
Annabel Boys
JMJohn Marsden
John Marsden
JSJohn Strang
John Strang
This study uses a functional perspective to examine the reasons young people cite for using psychoactive substances. The study sample comprised 364 young poly-drug users recruited using snowball-sampling methods. Data on lifetime and recent frequency and intensity of use for alcohol, cannabis, amphetamines, ecstasy, LSD and cocaine are presented. A majority of the participants had used at least one of these six drugs to fulfil 11 of 18 measured substance use functions. The most popular functions for use were using to: relax (96.7%), become intoxicated (96.4%), keep awake at night while socializing (95.9%), enhance an activity (88.5%) and alleviate depressed mood (86.8%). Substance use functions were found to differ by age and gender. Recognition of the functions fulfilled by substance use should help health educators and prevention strategists to make health messages about drugs more relevant and appropriate to general and specific audiences. Targeting substances that are perceived to fulfil similar functions and addressing issues concerning the substitution of one substance for another may also strengthen education and prevention efforts.

20 February 2003 in Addiction
Verified
Journal Article
Closed access
PDF file
MGMichael Gossop
Michael Gossop
JMJohn Marsden
John Marsden
DSDuncan Stewart
Duncan Stewart
TKTara Kidd
Tara Kidd